News from cepheid A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Dec 03, 2015, 08:03 ET FIND And Cepheid Announce A Strategic Collaboration To Advance Point-Of-Care TB Diagnosis

FIND and Cepheid (Nasdaq: CPHD) today announced that they are broadening their collaboration on bringing point-of-care tuberculosis (TB) diagnosis to ...


Dec 01, 2015, 08:05 ET Cepheid Commemorates World AIDS Day

Cepheid (Nasdaq: CPHD) today announced that it had been named as a supplier of HIV Viral Load and early infant diagnostics by the Global Fund as one...


Dec 01, 2015, 08:03 ET Cepheid Reaffirms 2015 Outlook At Piper Jaffray Healthcare Conference

Cepheid (Nasdaq: CPHD) today announced that, as part of its participation at the Piper Jaffray Healthcare Conference in New York City later this...


Nov 24, 2015, 04:05 ET Cepheid to Webcast Upcoming Financial Presentation

Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conference, and invited investors to participate via...


Nov 16, 2015, 08:00 ET Cepheid Supports Inaugural Antibiotic Awareness Week

Cepheid (Nasdaq: CPHD) today announced its support of World Antibiotic Awareness Week, a global campaign led by the World Health Organization (WHO)...


Oct 20, 2015, 04:05 ET Cepheid Reports 2015 Third Quarter Results

Cepheid (Nasdaq: CPHD) today reported revenue for the third quarter of 2015 of $126.5 million, representing growth of 10% from $115.2 million for the ...


Oct 13, 2015, 04:03 ET Cepheid Reports Preliminary Results For 2015 Third Quarter

Cepheid (Nasdaq: CPHD) today announced preliminary results for the quarter ending September 30, 2015. Based on Cepheid's preliminary financial...


Jul 29, 2015, 07:03 ET 'Superbug' Test Updated to Identify Newest Carbapenem-Resistant Organisms

Cepheid (Nasdaq: CPHD) today announced the international availability of an update to Xpert® Carba-R, with the addition of two newly emerging...


Jul 28, 2015, 07:05 ET World's First "Go-Anywhere" Molecular Diagnostic System Unveiled at AACC

Cepheid (Nasdaq: CPHD) today unveiled the GeneXpert® Omni, a flexible and portable clinical molecular diagnostic system designed to meet the needs of ...


Jul 28, 2015, 07:05 ET World's Most Portable Molecular Diagnostics System Unveiled at AACC

Cepheid (Nasdaq: CPHD) and FIND today unveiled the GeneXpert® Omni, the world's most portable molecular diagnostics system enabling unprecedented...


Jul 23, 2015, 04:03 ET Cepheid Reports 2015 Second Quarter Results

Cepheid (Nasdaq: CPHD) today reported revenue for the second quarter of 2015 of $132.5 million, representing growth of 14% from $116.5 million for...


Jul 06, 2015, 07:00 ET Cepheid Schedules 2015 Second Quarter Results Announcement And Webcast

Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2015 second quarter ended June 30, 2015 on Thursday, July 23,...


Jun 09, 2015, 07:00 ET Cepheid Announces Analyst Event And Webcast

Cepheid (Nasdaq: CPHD) today announced that the company will host a Financial Analyst Event on Monday, July 27th at the 2015 AACC Meeting being held...


May 13, 2015, 07:00 ET WHO Lists Cepheid's Xpert Ebola as Eligible for Procurement to Ebola Affected Countries

Cepheid (Nasdaq: CPHD) today announced that the World Health Organization (WHO) has assessed and listed Xpert® Ebola as eligible for procurement to...


May 07, 2015, 04:19 ET Cepheid to Webcast Upcoming Financial Presentations

Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via...


Apr 23, 2015, 04:05 ET Cepheid Reports 2015 First Quarter Results

Cepheid (Nasdaq: CPHD) today reported revenue for the first quarter of 2015 of $132.6 million, representing growth of 24% from $106.9 million for the ...


Apr 16, 2015, 07:00 ET Cepheid and FIND Announce European Approval of Xpert HIV-1 Qual

Cepheid (Nasdaq: CPHD) and FIND today announced that Xpert® HIV-1 Qual, a qualitative 90-minute molecular HIV test, has achieved CE-IVD status under...


Apr 15, 2015, 07:00 ET Cepheid Announces European Approval of Xpert HCV Viral Load

Cepheid (NASDAQ: CPHD) today announced that Xpert® HCV Viral Load, a quantitative test that provides on-demand molecular testing for confirmation of...


Apr 07, 2015, 04:07 ET Cepheid Welcomes Executive Vice President And Chief Financial Officer

Cepheid (Nasdaq: CPHD) today announced that it has appointed Mr. Ilan Daskal to the position of Executive Vice President and Chief Financial Officer, ...


Apr 07, 2015, 04:05 ET Cepheid Schedules 2015 First Quarter Results Announcement And Webcast

Cepheid (Nasdaq: CPHD) today announced that it will report financial results for its 2015 first quarter ended March 31, 2015 on Thursday, April 23,...


Mar 24, 2015, 07:00 ET On World TB Day 2015 Cepheid and NHLS Commemorate Global Shipment of the 10 Millionth Xpert MTB/RIF Test Cartridge

Cepheid (Nasdaq: CPHD) and the National Health Laboratory Service (NHLS) in South Africa today recognized World TB Day 2015 by commemorating the...


Mar 24, 2015, 04:05 ET Cepheid Receives Emergency Use Authorization from FDA for Xpert Ebola Diagnostic Test

Cepheid (Nasdaq: CPHD) today announced it has received Emergency Use Authorization from the U.S. Food & Drug Administration (FDA) for Xpert® Ebola, a ...


Feb 18, 2015, 04:05 ET Cepheid to Webcast Upcoming Financial Presentations

Cepheid (NASDAQ: CPHD) today announced that its executives will be speaking at the following conferences, and invited investors to participate via...


Feb 13, 2015, 07:00 ET Cepheid Receives FDA Clearance for Expanded Claims on Tuberculosis Test

Cepheid (Nasdaq: CPHD) today announced it has received clearance from the U.S. Food & Drug Administration (FDA) for expanded claims on its Xpert®...


Jan 29, 2015, 04:05 ET Cepheid Reports Fourth Quarter And Full Year 2014 Results

Cepheid (Nasdaq: CPHD) today reported revenue for the fourth quarter of 2014 of $131.5 million. Net loss was $23.8 million, or $(0.34) per share,...